Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$6.7 - $24.21 $581,178 - $2.1 Million
86,743 Added 1.55%
5,666,347 $137 Million
Q4 2022

Feb 13, 2023

BUY
$4.52 - $10.57 $2.48 Million - $5.81 Million
549,256 Added 10.92%
5,579,604 $59 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.62 $1.46 Million - $2.38 Million
424,311 Added 9.21%
5,030,348 $22.6 Million
Q2 2022

Aug 12, 2022

BUY
$3.65 - $7.3 $782,147 - $1.56 Million
214,287 Added 4.88%
4,606,037 $18.4 Million
Q1 2022

May 12, 2022

SELL
$3.4 - $7.88 $313,395 - $726,339
-92,175 Reduced 2.06%
4,391,750 $32.1 Million
Q4 2021

Feb 10, 2022

SELL
$5.59 - $7.39 $38,017 - $50,259
-6,801 Reduced 0.15%
4,483,925 $25.2 Million
Q3 2021

Nov 09, 2021

SELL
$5.66 - $8.33 $319,342 - $469,986
-56,421 Reduced 1.24%
4,490,726 $28.7 Million
Q2 2021

Aug 11, 2021

BUY
$6.71 - $11.04 $30.5 Million - $50.2 Million
4,547,147 New
4,547,147 $38.3 Million

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.